biotech

A Crucial Major Depressive Disorder Study Is About to Be Underway

After Axsome Therapeutics Inc. (NASDAQ: AXSM) announced that it has completed patient enrollment in its Gemini study, a Phase 3 trial of AXS-05 in patients with major depressive disorder (MDD), ...
Read Full Story »

Are Shareholders Getting Enough in the Achillion Acquisition?

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). While shares are up sharply ...
Read Full Story »

Why This Neuromuscular Disorder Study Could Be the Next Big Thing

Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial. Specifically, the results are from Reata’s MOXIe Phase ...
Read Full Story »

New Osteoarthritis Treatment Has to Wait Even Longer for FDA Approval

Flexion Therapeutics Inc. (NASDAQ: FLXN) has announced that the U.S. Food and Drug Administration (FDA) informed the company that it needs additional time to complete the review of the supplemental ...
Read Full Story »

Are Shareholders Getting Enough From the Ra Pharma Acquisition?

Ra Pharmaceuticals Inc. (NASDAQ: RARX) shares more than doubled on Thursday after the announcement that UCB would acquire the firm. The boards of directors of both companies have unanimously approved ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 30. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Ovarian Cancer Treatment Takes the Next Big Step and Hits the Fast Track

In 2019, the American Cancer Society estimates that about 22,530 women will receive a new diagnosis of ovarian cancer and that about 13,980 women will die from this disease in ...
Read Full Story »

Major Step Forward in Peanut Allergy Treatment

DBV Technologies S.A. (NASDAQ: DBVT) shares dipped early Monday after the firm announced an update from the U.S. Food and Drug Administration (FDA). Although it was a positive update for ...
Read Full Story »

More Good News for LGMD Patients

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped on Friday after the firm announced an update from its Limb-girdle muscular dystrophy Type 2E (LGMD2E) trial. Specifically, Sarepta announced the nine-month functional ...
Read Full Story »

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April. Even the biggest and ...
Read Full Story »

Are Biotechs the Next Target for Cyber Criminals?

After Minerva Neurosciences Inc. (NASDAQ: NERV) announced that it was the victim of a cyberattack, its shares dropped sharply on Tuesday. Minerva also provided an update on its clinical trials. ...
Read Full Story »

Major Duchenne Muscular Dystrophy Trial Is Ready to Launch

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment is for the Phase 3 PolarisDMD trial ...
Read Full Story »

Why This Successful Bladder Cancer Study May Not Be Enough

Immunomedics Inc. (NASDAQ: IMMU) shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual ...
Read Full Story »

Ovarian Cancer Study Suffers Big Setback

ImmunoGen Inc. (NASDAQ: IMGN) has released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. Specifically, this data comes ...
Read Full Story »

Are Dova Pharma Investors Getting the Most Out of This Acquisition?

Dova Pharmaceuticals Inc. (NASDAQ: DOVA) shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. Through this acquisition, Sobi is looking ...
Read Full Story »